MindMed To Begin Clinical Trials On Ayahuasca's Active Ingredient DMT
Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) (OTC: MMEDF) announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with
